echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Food Articles > The new coronary pneumonia immune response male and female patients have a stronger and more sustained T-cell response.

    The new coronary pneumonia immune response male and female patients have a stronger and more sustained T-cell response.

    • Last Update: 2020-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    BEIJING, Aug. 30 (Xinhua Zhang Mengran) The British journal Nature published on the 26th of an immunological study, outlining the differences in the immune response of men and women with new coronary pneumonia patients. These findings may help guide the use of a gender-based approach to the treatment of male and female patients.
    studies have shown that male patients are more severe than women, but the root cause of this difference is not clear. To gain insight into the problem, a team at Yale University School of Medicine assessed 98 patients diagnosed with mild to moderate neo-coronary pneumonia at Yale-New Blackrne Hospital in the United States, aged 18 or older, with an average age of 61 to 64.
    team found that female patients developed stronger and more sustained T-cell responses than male patients. T-cells are an important part of the immune system and their role includes killing infected cells. Poor T-cell response in male patients was associated with poor disease outcomes.
    patients with neocyto pneumonia had higher levels of innate immunocytokines and coercides (these signaling molecules were involved in raising immune cells to inflammatory sites) compared to healthy control groups. However, some of these factors have higher levels in male patients than in female patients. In female patients, higher levels of congenitic immunocytokines were associated with poor disease response.
    results suggest that male patients may benefit from therapy that improves T-cell response, while female patients may benefit from therapy that inhibits early congenitic immune responses. Still, the researchers caution that they can't rule out other potential factors that could alter the risk of poor prognosticity in both male and female patients.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.